Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Feb;79(1):76-93.
doi: 10.1111/1747-0080.12672. Epub 2021 May 7.

Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis

Joanna Giang  1 , Xiao Lan  1 , Megan Crichton  2 , Wolfgang Marx  2   3 , Skye Marshall  2   4
Affiliations
Meta-Analysis

Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis

Joanna Giang et al. Nutr Diet. 2022 Feb.

Abstract

Aim: Biophenol-rich nutraceuticals may be an adjuvant treatment for Crohn's disease (CD), ulcerative colitis (UC), symptomatic uncomplicated diverticular disease (SUDD), and irritable bowel syndrome (IBS). This systematic review and meta-analysis aimed to determine the efficacy and safety of biophenol-rich nutraceutical supplementation on CD, UC, SUDD, and IBS on gastrointestinal symptoms (GIS), quality of life (QoL), inflammatory and oxidative stress biomarkers, and adverse events compared to usual care or placebo.

Methods: PubMed, Embase, CINAHL, and CENTRAL were searched for randomised controlled trials until 27 April 2020. Outcomes were GIS, inflammatory and oxidative stress markers, QoL, and adverse events. The Cochrane Risk of Bias tool and GRADE were used to appraise studies. Data were pooled using Revman.

Results: Twenty-three trials in CD, UC, and IBS patients were included. Compared with placebo, biophenol-rich nutraceuticals improved GIS (SMD: 0.43 [95%CI: 0.22, 0.63]; GRADE: very low) in UC, CD, and IBS participants. In UC and CD participants, biophenol-rich nutraceuticals improved CRP by 1.6 mg/L [95%CI:0.08, 3.11; GRADE: low], malondialdehyde by 1 mmol/L [95%CI:0.55, 1.38; GRADE: low]; but only resveratrol improved QoL (SMD: -0.84 [95%CI: -1.24, -0.44; GRADE: high). Resveratrol (for UC and CD participants) and peppermint oil (for IBS participants) had greater certainty in the evidence for improving GIS and QoL (GRADE: moderate to high). There was no effect on adverse events (P > .05).

Conclusions: Biophenol-rich nutraceuticals may be an effective and safe adjuvant treatment for the management of CD, UC, and IBS; with higher certainty of evidence for resveratrol for UC and CD and peppermint oil for IBS.

Keywords: Crohn disease; diverticular diseases; inflammatory bowel diseases; irritable bowel syndrome; polyphenols; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no actual or potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Risk of bias summary of randomised controlled trials examining the effect of biophenol‐rich nutraceuticals on gastrointestinal symptoms and related outcomes in adults with inflammatory related gastrointestinal conditions
FIGURE 2
FIGURE 2
Gastrointestinal symptoms of adults with inflammatory bowel disease or irritable bowel syndrome after treatment with biophenol‐rich nutraceuticals or placebo per nutraceutical type
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS‐specific models of care? Therap Adv Gastroenterol. 2017;10(9):727‐736. - PMC - PubMed
    1. M'Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33‐47. - PMC - PubMed
    1. Yamamoto‐Furusho JK, Sarmiento‐Aguilar A, Toledo‐Mauriño JJ, et al. Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000‐2017). Medicine (Baltimore). 2019;98(27):e16291‐e16291. - PMC - PubMed
    1. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence‐based medicine. World J Gastroenterol. 2014;20(22):6759‐6773. - PMC - PubMed
    1. Fakhoury M, Negrulj R, Mooranian A, Al‐Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113‐120. - PMC - PubMed